Se prevé que el mercado de anticuerpos monoclonales alcance los 243.050 millones de dólares en 2028, frente a los 111.010 millones de dólares de 2021; se espera que crezca a una tasa compuesta anual del 11,8 % entre 2021 y 2028.
La creciente prevalencia del cáncer y otras enfermedades crónicas, y un tremendo aumento de los casos de COVID-19 en varias regiones son los factores clave que impulsan el crecimiento del mercado. Según el Fondo Mundial para la Investigación del Cáncer y el Instituto Americano del Cáncer, en 2020 se registraron ~18,1 millones de casos de cáncer, incluidos 9,3 millones de casos en hombres y 8,8 millones de casos en mujeres. El uso de anticuerpos monoclonales en el tratamiento de varios tipos de cáncer aún se encuentra en ensayos de fase 2 y fase 3.
Perspectivas estratégicas
Es probable que América del Norte continúe su dominio en el mercado de anticuerpos monoclonales durante 2021-2028. Estados Unidos tiene la mayor participación del mercado en esta región y se espera que siga siendo un accionista dominante en el mercado durante el período previsto. Según las estadísticas publicadas por Globocan 2020, se diagnosticaron ~1.806.590 nuevos casos de cáncer en EE. UU. y ~606.520 personas murieron a causa de esta enfermedad. Según un informe del Departamento de Comercio de Estados Unidos, su Instituto Nacional de Estándares y Tecnología (NIST) anunció la financiación de 153 millones de dólares al Instituto Nacional para la Innovación en la Fabricación de Biofarmacéuticos. Además, la FDA ha estado brindando apoyo para el desarrollo de anticuerpos monoclonales durante la prevalencia de COVID-19.
regiones lucrativas para el mercado de anticuerpos monoclonales
  ;
Perspectivas del mercado
El aumento significativo en la prevalencia del cáncer y otras enfermedades crónicas impulsa el crecimiento del mercado
Según la Sociedad Estadounidense del Cáncer Según el informe, ~16,9 millones de personas con antecedentes de cáncer residían en los EE. UU. en enero de 2019. Para enero de 2030, se estima que la población de sobrevivientes de cáncer aumentará a 22,1 millones debido únicamente al crecimiento y envejecimiento de la población. Por lo tanto, con la creciente prevalencia del cáncer y otras enfermedades crónicas, también ha aumentado la demanda de productos biológicos, como los anticuerpos monoclonales (mAB). Al ser componentes principales de muchos regímenes terapéuticos y tratamientos rentables, los productos biológicos desempeñan un papel clave en el tratamiento del cáncer.
Información basada en fuentes
En origen, el mercado de anticuerpos monoclonales está segmentado en murino, quimérico, humano y humanizado. Se estima que el segmento humano representará la mayor cuota de mercado durante 2021-2028. El crecimiento del mercado de este segmento se atribuye al aumento debido a la integración de anticuerpos monoclonales humanos para el tratamiento de diversos tipos de enfermedades infecciosas. Por ejemplo, Regeneron lanzó juntos un cóctel de anticuerpos casirivimab e imdevimab aprobado por la FDA para su uso en COVID-19. El medicamento ha recibido la Autorización de uso de emergencia (EUA) de la FDA. Se utiliza para el tratamiento de la COVID-19 leve a moderada en adultos y en pacientes pediátricos de al menos 12 años de edad y que pesen al menos 40 kg. Además, un aumento en su uso en diversas enfermedades crónicas y el empleo de tecnología avanzada de ingeniería genética se encuentran entre los factores importantes que impulsan el crecimiento del segmento de mercado.
Mercado de anticuerpos monoclonales, por Fuente: 2020 y 2028
Información basada en indicaciones
Basado en indicación, cáncer, enfermedades autoinmunes, enfermedades inflamatorias, enfermedades infecciosas, enfermedades microbianas y otras. El segmento del cáncer dominaría el mercado en los próximos años. Los avances relacionados con la aplicación terapéutica de los anticuerpos monoclonales han permitido su implementación exitosa en los tratamientos de diversos tipos de cáncer, como el cáncer de mama, el cáncer de pulmón y el cáncer de colon. Los medicamentos basados en estos anticuerpos ayudan a detectar células cancerosas, desencadenar la destrucción de las membranas celulares, bloquear los inhibidores del sistema inmunológico, etc. La FDA, en junio de 2020, aprobó dos medicamentos: olaparib y rucaparib para el tratamiento del cáncer de próstata. El fármaco es especialmente eficaz entre hombres con enfermedades de cáncer de próstata que se han diseminado o metastatizado y han dejado de responder a los tratamientos hormonales estándar, es decir, una enfermedad resistente a la castración.
Usuario final- Información basada en
Por usuario final, el mercado de anticuerpos monoclonales se segmenta en hospitales, institutos de investigación y otros. El segmento hospitalario tiene la mayor cuota de mercado debido a la creciente adopción de mAB como línea de tratamiento preferida, especialmente para el tratamiento del cáncer.
Las empresas que operan en el mercado de anticuerpos monoclonales adoptan la estrategia de innovación de productos para satisfacer las cambiantes demandas de los clientes en todo el mundo, lo que también les permite mantener su marca en el mercado global.
Mercado de anticuerpos monoclonales - Segmentación< /h3>
Según la fuente, el mercado de anticuerpos monoclonales se segmenta en humanos, humanizados, quiméricos y murinos. Por método de producción, el mercado se segmenta en in vitro e in vivo. El mercado de anticuerpos monoclonales, por indicación, se segmenta aún más en cáncer, enfermedades autoinmunes, enfermedades infecciosas, enfermedades inflamatorias, enfermedades microbianas y otras. Por aplicación, el mercado se subsegmenta en aplicaciones terapéuticas, aplicaciones de diagnóstico y aplicaciones de investigación. Además, según el usuario final, el mercado se segmenta en hospitales, otros e institutos de investigación.
Mercado de anticuerpos monoclonales - por geografía
- América del Norte
- Estados Unidos
- Canadá
- México
- Europa
- Francia
- Alemania
- Italia
- Reino Unido
- España
- Resto de Europa
- Asia Pacífico (APAC)
- China
- India
- Corea del Sur
- Japón
- Australia
- Resto de APAC
- Oriente Medio y África (MEA)
- Sudáfrica
- Arabia Saudita
- EAU
- Resto de MEA
- América del Sur y Central (SCAM)
- Brasil
- Argentina
- Resto de ESTAFA
Perfiles de Empresas- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc
- Amgen, Inc
- Daiichi Sankyo Company, Limitado
- F. Hoffmann-La Roche AG
- AstraZeneca
- Elli Lily and Company
- Bayer AG
- Bristol-Myers Squibb Company
< /ul>
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Global monoclonal antibodies market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for monoclonal antibodies market. The US is estimated to hold the largest share in the monoclonal antibodies market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of R&D activities is the key factor responsible for the Asia-Pacific regional growth for monoclonal antibodies accounting fastest growth of the region during the coming years.
Novartis AG, Pfizer, Inc., GlaxoSmithKline Plc, Amgen, Inc., Daiichi Sankyo Company, Limited, F.Hoffmann-La Roche AG, AstraZeneca, Elli Lilly and Company, Bayer AG, Bristol-Myers Squibb Company are among the leading companies operating in the global monoclonal antibodies market
The in vitro segment dominated the global monoclonal antibodies market and accounted for the largest revenue of 75,044.50 Mn in 2021.
Food and Drug Administration (FDA) defines monoclonal antibodies as immunoglobulin molecules that are secreted from a population of identical cells. They are homogenous in structure and binding specificity. These are used as multifunctional components for the immune system. They facilitate numerous cellular and humoral reactions to a variety of antigens, which include host and foreign substances.
Significant rise in the cancer and chronic diseases is one of the most significant factors responsible for the overall market growth.
Based on source, human segment took the forefront lead in the worldwide market by accounting largest share in 2020 and is expected to continue to do so till the forecast period.
The List of Companies - Monoclonal Antibody Market
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc
- Amgen, Inc
- Daiichi Sankyo Company, Limited
- F. Hoffmann-La Roche AG
- AstraZeneca
- Elli Lilly and Company
- Bayer AG
- Bristol-Myers Squibb Company
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Jan 2022
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Jan 2022
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2022
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Jan 2022
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Jan 2022
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Jan 2022
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Jan 2022
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)